Genentech’s new stroke drug is delivered as a single five-second intravenous (IV) bolus, whereas Activase is administered as ...

SOUTH SAN FRANCISCO, Calif., March 03, 2025--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved ...

The existing treatment for acute ischemic stroke, "Activase," which was also developed by Genentech, took 60 minutes to complete intravenous administration. In contrast, TNKase can complete ...

Stroke is the fifth leading cause of death in the United States and a major cause of disability, affecting over 795,000 people each year. ... Genentech, part of the Roche group, ...

Stroke is the fifth-leading cause of death and the leading cause of long-term disability in the U.S., affecting more than 795,000 people each year, according to Genentech. Related ...

FDA approves Genentech’s TNKase® in acute ischemic stroke in adults. News release. Genentech. March 3, 2025. https: ...

NEW ORLEANS -- Tenecteplase in recent years outpaced alteplase as the stroke thrombolytic of choice at one large hospital system, despite shrinking cost savings, a researcher reported here. In ...

Before TNKase, Activase was the only pharmacological treatment approved by the FDA for acute ischemic stroke. Whilst Genentech has enjoyed market domination since 1996 – the year in which ...

About Genentech in Stroke For decades, Roche and Genentech have been conducting neuroscience research and clinical trials aimed at exploring areas of the highest medical need.

Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) has approved TNKase® (tenecteplase), a thrombolytic or clot-dissolving agent, for the ...

The FDA has approved TNKase, a tissue plasminogen, clot-dissolving agent, to treat acute ischemic stroke in adults, according to the manufacturer.Genentech said in a press release that TNKase ...